![Erwin Boos](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Erwin Boos
Direttore/Membro del Consiglio presso Kymab Group Ltd.
Posizioni attive di Erwin Boos
Società | Posizione | Inizio | Fine |
---|---|---|---|
Schroder Adveq Management AG
![]() Schroder Adveq Management AG Investment ManagersFinance Schroder Adveq Management AG (Schroder Adveq Management) is a private equity subsidiary of Schroders Plc. The firm was founded by Bruno Raschle in 1997 and is headquartered in Zurich, Switzerland. | Investitore di Private Equity | 01/01/2006 | - |
Kymab Ltd.
![]() Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | Direttore/Membro del Consiglio | - | - |
Kymab Group Ltd.
![]() Kymab Group Ltd. Pharmaceuticals: MajorHealth Technology Part of Sanofi, Kymab Group Ltd. is a British biopharmaceutical company that develops human monoclonal antibody drugs. The company is based in Cambridge, UK. The company was founded in 2016 by Alan Bradley. Kymab Group was acquired by Sanofi Foreign Participations BV on April 09, 2021 for $1,970.99 million. | Direttore/Membro del Consiglio | 21/04/2020 | - |
Storia della carriera di Erwin Boos
Precedenti posizioni note di Erwin Boos
Società | Posizione | Inizio | Fine |
---|---|---|---|
MISSION Therapeutics Ltd.
![]() MISSION Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology MISSION Therapeutics Ltd. develops small molecule drugs targeting enzymes involved in cancer and other diseases. It focuses on selectively targeting deubiquitylating enzymes to treat cancer, neurodegenerative and other diseases. The company was founded by Stephen Jackson Philip, Xavier Jacq, Niall M. B. Martin and Keith Menear in 2011 and is headquartered in Cambridge, the United Kingdom. | Direttore/Membro del Consiglio | - | 24/03/2021 |
Statistiche
Distribuzione geografica
Regno Unito | 4 |
Svizzera | 2 |
Posizioni
Director/Board Member | 3 |
Private Equity Investor | 1 |
Settori
Health Technology | 4 |
Finance | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Aziende private | 4 |
---|---|
Schroder Adveq Management AG
![]() Schroder Adveq Management AG Investment ManagersFinance Schroder Adveq Management AG (Schroder Adveq Management) is a private equity subsidiary of Schroders Plc. The firm was founded by Bruno Raschle in 1997 and is headquartered in Zurich, Switzerland. | Finance |
Kymab Ltd.
![]() Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
Kymab Group Ltd.
![]() Kymab Group Ltd. Pharmaceuticals: MajorHealth Technology Part of Sanofi, Kymab Group Ltd. is a British biopharmaceutical company that develops human monoclonal antibody drugs. The company is based in Cambridge, UK. The company was founded in 2016 by Alan Bradley. Kymab Group was acquired by Sanofi Foreign Participations BV on April 09, 2021 for $1,970.99 million. | Health Technology |
MISSION Therapeutics Ltd.
![]() MISSION Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology MISSION Therapeutics Ltd. develops small molecule drugs targeting enzymes involved in cancer and other diseases. It focuses on selectively targeting deubiquitylating enzymes to treat cancer, neurodegenerative and other diseases. The company was founded by Stephen Jackson Philip, Xavier Jacq, Niall M. B. Martin and Keith Menear in 2011 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
- Borsa valori
- Insiders
- Erwin Boos
- Esperienza